Joannie Shen; Michael Johnston; Ron D Hays


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(4):447-453. 

In This Article

Asthma Control

With the growing recognition of the importance of the patient's perspective,[4–6] current leading asthma guidelines, including the Global Initiative for Asthma and Expert Panel Report 3, have consistently identified asthma control as the focal concept for asthma. Asthma-practice guidelines traditionally focused on optimizing lung function, minimizing symptoms and preventing exacerbations. Lung function was regarded as the primary end point in earlier guidelines,[7,8] until recent findings on the poor correlation between lung function, inflammation and symptoms.[9,10] Both clinical practices and clinical trials have focused increasingly on assessing asthma control. Asthma control incorporates the global assessment of symptoms, use of rescue or reliever medicine or both, lung function and patient-reported functioning and activity limitations.

Asthma control can be defined as the extent to which manifestations of asthma are reduced by treatment. The concept that asthma control ought to encompass not only a patient's current or recent clinical state, but also future risk of exacerbation and side effects from therapeutic interventions, is increasingly recognized. Because asthma control is a multidimensional construct without universally recognized criterion standards, the criteria used to assess asthma control have varied widely from study to study. Therefore, harmonizing the measures of asthma control is important for assessing the efficacy of therapeutic interventions in patients with asthma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.